5-ALA and FDA approval for glioma surgery - PubMed (original) (raw)
Review
5-ALA and FDA approval for glioma surgery
Constantinos G Hadjipanayis et al. J Neurooncol. 2019 Feb.
Abstract
The US Food and Drug Administration (FDA) approved 5-aminolevulinic acid (5-ALA; Gleolan®; photonamic GmbH and Co. KG) for use as an intraoperative optical imaging agent in patients with suspected high-grade gliomas (HGGs) in 2017. This was the first ever optical imaging agent approved as an adjunct for the visualization of malignant tissue during surgery for brain tumors. The approval occurred a decade after European approval and a multicenter, phase III randomized trial which confirmed that surgeons using 5-ALA fluorescence-guided surgery as a surgical adjunct could achieve more complete resections of tumors in HGG patients and better patient outcomes than with conventional microsurgery. Much of the delay in the US FDA approval of 5-ALA stemmed from its conceptualization as a therapeutic and not as an intraoperative imaging tool. We chronicle the challenges encountered during the US FDA approval process to highlight a new standard for approval of intraoperative optical imaging agents in brain tumors.
Keywords: 5-ALA; Brain tumors; FDA; Glioblastoma; Gliomas; High-grade gliomas; Intraoperative imaging; Optical imaging.
Conflict of interest statement
Conflict of Interest:
Constantinos Hadjipanayis is a consultant for NXDC and Synaptive Medical Inc. He will receive royalties from NXDC. He has also received speaker fees by Carl Zeiss and Leica.
Walter Stummer has received speaker and consultant fees by Carl Zeiss, Leica, Photonamic, Medac, and NXDC
Figures
Figure 1.
5-ALA approval timeline.
Figure 2.
Summary of clinical benefit for patients undergoing 5-ALA FGS including tumor visualization with high diagnostic accuracy (high PPV), maximal EOR, and better PFS-6.
Similar articles
- 5-Aminolevulinic acid fluorescence guided surgery for recurrent high-grade gliomas.
Chohan MO, Berger MS. Chohan MO, et al. J Neurooncol. 2019 Feb;141(3):517-522. doi: 10.1007/s11060-018-2956-8. Epub 2018 Aug 10. J Neurooncol. 2019. PMID: 30097823 Review. - Fluorescence-guided surgery for high-grade gliomas.
Lakomkin N, Hadjipanayis CG. Lakomkin N, et al. J Surg Oncol. 2018 Aug;118(2):356-361. doi: 10.1002/jso.25154. Epub 2018 Aug 19. J Surg Oncol. 2018. PMID: 30125355 Review. - Established and emerging uses of 5-ALA in the brain: an overview.
Díez Valle R, Hadjipanayis CG, Stummer W. Díez Valle R, et al. J Neurooncol. 2019 Feb;141(3):487-494. doi: 10.1007/s11060-018-03087-7. Epub 2019 Jan 3. J Neurooncol. 2019. PMID: 30607705 Review. - The impact of 5-aminolevulinic acid on extent of resection in newly diagnosed high grade gliomas: a systematic review and single institutional experience.
Haider SA, Lim S, Kalkanis SN, Lee IY. Haider SA, et al. J Neurooncol. 2019 Feb;141(3):507-515. doi: 10.1007/s11060-018-03061-3. Epub 2018 Dec 1. J Neurooncol. 2019. PMID: 30506501 - A prospective Phase II clinical trial of 5-aminolevulinic acid to assess the correlation of intraoperative fluorescence intensity and degree of histologic cellularity during resection of high-grade gliomas.
Lau D, Hervey-Jumper SL, Chang S, Molinaro AM, McDermott MW, Phillips JJ, Berger MS. Lau D, et al. J Neurosurg. 2016 May;124(5):1300-9. doi: 10.3171/2015.5.JNS1577. Epub 2015 Nov 6. J Neurosurg. 2016. PMID: 26544781 Clinical Trial.
Cited by
- Fluorescence guidance in skull base surgery: Applications and limitations - A systematic review.
Suero Molina E, Bruneau M, Reuter G, Shahein M, Cavallo LM, Daniel RT, Kasper EM, Froelich S, Jouanneau E, Manet R, Messerer M, Mazzatenta D, Meling TR, Roche PH, Schroeder HW, Tatagiba M, Visocchi M, Prevedello DM, Stummer W, Cornelius JF; EANS Skull Base Section. Suero Molina E, et al. Brain Spine. 2024 Aug 29;4:103328. doi: 10.1016/j.bas.2024.103328. eCollection 2024. Brain Spine. 2024. PMID: 39309550 Free PMC article. Review. - Optical Methods for Optimizing Fluorescence Imaging Field of View and Image Quality in Surgical Guidance Procedures.
Seo J, Park J, Yoon K, Lee S, Kim M, Ryu SY, Kim KG. Seo J, et al. Diagnostics (Basel). 2024 Sep 9;14(17):1996. doi: 10.3390/diagnostics14171996. Diagnostics (Basel). 2024. PMID: 39272780 Free PMC article. - Tuning nanoparticle core composition drives orthogonal fluorescence amplification for enhanced tumour imaging.
Pan M, Zhao R, Fu C, Tang M, Zhou J, Ma B, Liu J, Yang Y, Chen B, Zhang Q, Wang Y. Pan M, et al. Nat Commun. 2024 Sep 7;15(1):7824. doi: 10.1038/s41467-024-52029-7. Nat Commun. 2024. PMID: 39242636 Free PMC article. - Gliomas in adults: Guidance on investigations, diagnosis, treatment and surveillance.
Lerner A, Palmer K, Campion T, Millner TO, Scott E, Lorimer C, Paraskevopoulos D, McKenna G, Marino S, Lewis R, Plowman N. Lerner A, et al. Clin Med (Lond). 2024 Sep;24(5):100240. doi: 10.1016/j.clinme.2024.100240. Epub 2024 Sep 2. Clin Med (Lond). 2024. PMID: 39233205 Free PMC article. Review. - 5-Aminolevulinic acid-mediated photodynamic therapy in combination with kinase inhibitor lapatinib enhances glioblastoma cell death.
Chandratre S, Merenich D, Myers K, Chen B. Chandratre S, et al. Apoptosis. 2024 Aug 27. doi: 10.1007/s10495-024-02012-w. Online ahead of print. Apoptosis. 2024. PMID: 39190205
References
- Stummer W, Stocker S, Wagner S, Stepp H, Fritsch C, Goetz C, Goetz AE, Kiefmann R, Reulen HJ (1998) Intraoperative detection of malignant gliomas by 5-aminolevulinic acid-induced porphyrin fluorescence. Neurosurgery 42: 518–525; - PubMed
- Parney IF, Chang SM (2003) Current chemotherapy for glioblastoma. Cancer J 9: 149–156 - PubMed
- Walker MD, Alexander E Jr., Hunt WE, MacCarty CS, Mahaley MS Jr., Mealey J Jr., Norrell HA, Owens G, Ransohoff J, Wilson CB, Gehan EA, Strike TA (1978) Evaluation of BCNU and/or radiotherapy in the treatment of anaplastic gliomas. A cooperative clinical trial. J Neurosurg 49: 333–343 doi:10.3171/jns.1978.49.3.0333 - DOI - PubMed
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical